Carolyn A Fahey1, Prosper F Njau2, Emmanuel Katabaro3, Rashid S Mfaume4, Nzovu Ulenga5, Natalino Mwenda6, Patrick T Bradshaw7, William H Dow8, Nancy S Padian7, Nicholas P Jewell9, Sandra I McCoy7. 1. Division of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA. Electronic address: cfahey@berkeley.edu. 2. Ministry of Health, Community Development, Gender, Elderly and Children, Dodoma, Tanzania; Health for a Prosperous Nation, Dar es Salaam, Tanzania. 3. Health for a Prosperous Nation, Dar es Salaam, Tanzania. 4. Ministry of Health, Community Development, Gender, Elderly and Children, Dodoma, Tanzania. 5. Management and Development for Health, Dar es Salaam, Tanzania. 6. Rasello, Dar es Salaam, Tanzania. 7. Division of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA. 8. Department of Health Policy and Management, School of Public Health, University of California, Berkeley, CA, USA. 9. Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.
Abstract
BACKGROUND: Financial incentives promote use of HIV services and might support adherence to the sustained antiretroviral therapy (ART) necessary for viral suppression, but few studies have assessed a biomarker of adherence or evaluated optimal implementation. We sought to determine whether varying sized financial incentives for clinic attendance effected viral suppression in patients starting ART in Tanzania. METHODS: In a three-arm, parallel-group, randomised controlled trial at four health facilities in Shinyanga region, Tanzania, adults aged 18 years or older with HIV who had started ART within the past 30 days were randomly assigned (1:1:1) using a tablet-based application (stratified by site) to receive usual care (control group) or to receive a cash incentive for monthly clinic attendance in one of two amounts: 10 000 Tanzanian Shillings (TZS; about US$4·50) or 22 500 TZS (about $10·00). There were no formal exclusion criteria. Participants were masked to the existence of two incentive sizes. Incentives were provided for up to 6 months via mobile health technology (mHealth) that linked biometric attendance monitoring to automated mobile payments. We evaluated the primary outcome of retention in care with viral suppression (<1000 copies per mL) at 6 months using logistic regression. This trial is registered with ClinicalTrials.gov, NCT03351556. FINDINGS:Between April 24 and Dec 14, 2018, 530 participants were randomly assigned to an incentive strategy (184 in the control group, 172 in the smaller incentive group, and 174 in the larger incentive group). All participants were included in the primary intention-to-treat analysis. At 6 months, approximately 134 (73%) participants in the control group remained in care and had viral suppression, compared with 143 (83%) in the smaller incentive group (risk difference [RD] 9·8, 95% CI 1·2 to 18·5) and 150 (86%) in the larger incentive group (RD 13·0, 4·5 to 21·5); we identified a positive trend between incentive size and viral suppression (p trend=0·0032), although the incentive groups did not significantly differ (RD 3·2, -4·6 to 11·0). Adverse events included seven (4%) deaths in the control group and 11 (3%) deaths in the intervention groups, none related to study participation. INTERPRETATION: Small financial incentives delivered using mHealth can improve retention in care and viral suppression in adults starting HIV treatment. Although further research should investigate the durability of effects from short-term incentives, these findings strengthen the evidence for implementing financial incentives within standard HIV care. FUNDING: National Institute of Mental Health at the US National Institutes of Health.
RCT Entities:
BACKGROUND: Financial incentives promote use of HIV services and might support adherence to the sustained antiretroviral therapy (ART) necessary for viral suppression, but few studies have assessed a biomarker of adherence or evaluated optimal implementation. We sought to determine whether varying sized financial incentives for clinic attendance effected viral suppression in patients starting ART in Tanzania. METHODS: In a three-arm, parallel-group, randomised controlled trial at four health facilities in Shinyanga region, Tanzania, adults aged 18 years or older with HIV who had started ART within the past 30 days were randomly assigned (1:1:1) using a tablet-based application (stratified by site) to receive usual care (control group) or to receive a cash incentive for monthly clinic attendance in one of two amounts: 10 000 Tanzanian Shillings (TZS; about US$4·50) or 22 500 TZS (about $10·00). There were no formal exclusion criteria. Participants were masked to the existence of two incentive sizes. Incentives were provided for up to 6 months via mobile health technology (mHealth) that linked biometric attendance monitoring to automated mobile payments. We evaluated the primary outcome of retention in care with viral suppression (<1000 copies per mL) at 6 months using logistic regression. This trial is registered with ClinicalTrials.gov, NCT03351556. FINDINGS: Between April 24 and Dec 14, 2018, 530 participants were randomly assigned to an incentive strategy (184 in the control group, 172 in the smaller incentive group, and 174 in the larger incentive group). All participants were included in the primary intention-to-treat analysis. At 6 months, approximately 134 (73%) participants in the control group remained in care and had viral suppression, compared with 143 (83%) in the smaller incentive group (risk difference [RD] 9·8, 95% CI 1·2 to 18·5) and 150 (86%) in the larger incentive group (RD 13·0, 4·5 to 21·5); we identified a positive trend between incentive size and viral suppression (p trend=0·0032), although the incentive groups did not significantly differ (RD 3·2, -4·6 to 11·0). Adverse events included seven (4%) deaths in the control group and 11 (3%) deaths in the intervention groups, none related to study participation. INTERPRETATION: Small financial incentives delivered using mHealth can improve retention in care and viral suppression in adults starting HIV treatment. Although further research should investigate the durability of effects from short-term incentives, these findings strengthen the evidence for implementing financial incentives within standard HIV care. FUNDING: National Institute of Mental Health at the US National Institutes of Health.
Authors: Myron S Cohen; M Kumi Smith; Kathryn E Muessig; Timothy B Hallett; Kimberly A Powers; Angela D Kashuba Journal: Lancet Date: 2013-10-23 Impact factor: 79.321
Authors: Carol S Camlin; Kara Marson; Alex Ndyabakira; Monica Getahun; Devy Emperador; Ambrose Byamukama; Dalsone Kwarisiima; Harsha Thirumurthy; Gabriel Chamie Journal: PLoS One Date: 2022-06-24 Impact factor: 3.752
Authors: Sara Lodi; Nneka I Emenyonu; Kara Marson; Dalsone Kwarisiima; Robin Fatch; Michael G McDonell; Debbie M Cheng; Harsha Thirumurthy; Monica Gandhi; Carol S Camlin; Winnie R Muyindike; Judith A Hahn; Gabriel Chamie Journal: Trials Date: 2021-05-20 Impact factor: 2.279
Authors: Laura Packel; Prosper Njau; Carolyn Fahey; Angela Ramadhani; William H Dow; Nicholas P Jewell; Sandra McCoy Journal: Trials Date: 2020-11-23 Impact factor: 2.279
Authors: Jean Népomuscène Nshimyumuremyi; Gerardine Mukesharurema; Josée Uwamariya; Elise Mutunge; Andrea S Goodman; Jean d'Amour Ndahimana; Dale A Barnhart Journal: J Int Assoc Provid AIDS Care Date: 2022 Jan-Dec
Authors: Malia Duffy; Caitlin Madevu-Matson; Jessica E Posner; Hana Zwick; Melissa Sharer; Antonia M Powell Journal: Trop Med Int Health Date: 2022-04-01 Impact factor: 3.918
Authors: Carolyn A Fahey; Prosper F Njau; Nicole K Kelly; Rashid S Mfaume; Patrick T Bradshaw; William H Dow; Sandra I McCoy Journal: BMJ Glob Health Date: 2021-12